The market opened in the red on 17th January. The previous day witnessed  the Sensex going up by 59.83 points to end at 41,932.56  and the Nifty was up by 12.20 points to close at 12,355.50.

The consolidated revenue for the quarter Q3FY20 came in at Rs 533.6 crore, as against Rs 417.35 crore in the corresponding quarter last year, registering 27.9 per cent YoY increase. In this quarter, domestic business grew by 35 per cent YoY and international sales by 24 per cent YoY.

The market opened in the red on 17th January. The previous day witnessed  the Sensex going up by 59.83 points to end at 41,932.56  and the Nifty was up by 12.20 points to close at 12,355.50. 

The Supreme Court of India has lifted the suspension of Environment Clearance (EC) imposed on the construction of a new greenfield airport at Mopa (Goa) of GMR Goa International Airport Limited (GGIAL), which is a subsidiary of GMR Infrastructure Limited.

A close below 12,270 may provide some bearish signs for the short-term. As long as it does not close below the prior bar low, be with the positive bias for the target of 12,400 and above. Stocks in news: Rallis India, Shriram Transport Finance, GMR Infrastructure, Premier Explosives, Nilkamal.

In the previous trading sessions, markets celebrated the phase 1 of the trade deal but that did not last long as the markets gave away most of its gains. As we enter the final trading session of the week, the SGX Nifty is trading flat and is likely to be cautious ahead of the weekend.

The concern of financing retirement is usually pondered over in one’s early 40’s. So, how should you go for planning your retirement in early 40’s? Let’s find out!

The following stocks will be in focus during Friday’s trading session in the light of their result announcements: Tata Consultancy Services, HCL Technologies, L&T Finance Holdings, Reliance Industries and ICICI Lombard General Insurance Company.

On Thursday Wockhardt announced that the Drug Controller General of India (DCGI) has approved two of its new antibiotics, EMROK (IV) and EMROK-O for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteraemia, thereby, becoming the first Indian company to achieve approval for newly-discovered antibiotics.